ILMN vs. PACB

In the year-to-date period, ILMN achieves a -40.60% return, which is significantly higher than PACB's -46.38% return. Over the past 10 years, ILMN has outperformed PACB with an annualized return of -8.80%, while PACB has yielded a comparatively lower -16.19% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Illumina, Inc. (ILMN) and Pacific Biosciences of California, Inc. (PACB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ILMN Sharpe Ratio is -0.56, which is comparable to the PACB Sharpe Ratio of -0.43. The chart below compares the historical Sharpe Ratios of ILMN and PACB, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither ILMN nor PACB has paid dividends to shareholders.

The maximum ILMN drawdown since its inception was -96.14%, roughly equal to the maximum PACB drawdown of -98.08%. Use the drawdown chart below to compare losses from any high point for ILMN and PACB. For additional features, visit the drawdowns tool.

Illumina, Inc. (ILMN) and Pacific Biosciences of California, Inc. (PACB) have volatilities of 14.76% and 14.70%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Illumina, Inc. and Pacific Biosciences of California, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.